ArticleDiscover oncology2026
Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC). This study aimed to elucidate the role of OXA in regulating Cysteine-rich protein 61 (Cyr61) expression via the Hippo-Yes-associated protein (YAP) pathway in the context of chemotherapy-induced drug resistance.
methodsWe used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.
resultsThe results revealed that exposure to varying concentrations of OXA for 24 h induced increased mRNA and protein levels of Cyr61 in HCT8 and HCT116 CRC cells. Mechanistically, OXA-mediated overexpression of Cyr61 in CRC cells was attributed to inhibition of the Hippo-YAP pathway.
conclusionsThese findings provide novel insights into the mechanisms underlying chemotherapy-induced drug resistance in CRC and highlight the release of Cyr61 by CRC cells as a potential therapeutic target for overcoming OXA resistance in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.